Table 1.

Clinical Characteristics and Response.

Parameter	Value	Evaluable No. patients	CR No. patients (%)	PR No. patients (%)	SD No. patients (%)	PD No. patients (%)
Number of patients	31	28	17 (60.7%)	8 (28.5%)	1 (3.5%)	2 (7.1%)
Age, median y (range)	49 (17-77)
Gender (M / F)	15M / 16F
Ann Arbor stage no. patients (%)
Stage I-II	3 (9.6%)
Stage III-IV	28 (90.3%)
IPI score no. patients (%)
Low + Low-intermediate (0-2)	11 (35.4%)
High-intermediate +High (3-5)	20 (64.5%)
Histologic subtype no. patients(%)
PTCL-NOS	11 (35.4%)	10	7 (70%)	3 (30%)
ATL	10 (32.2%)	8	5 (62.5%)	2 (25%)	1 (12.5%)
AITL	4 (12.9%)	4	3 (75%)	1 (25%)
CGDTCL	2 (6.4%)	2		1 (50%)		1 (50%)
Hepatosplenic TCL	2 (6.4%)	2		1 (50%)		1 (50%)
Other*	2 (6.4%)	2	2 (100%)

Abbreviations: PTCL-NOS, peripheral T cell lymphoma not-otherwise-specified; ATL, adult T cell leukemia/lymphoma; AITL, angioimmunoblastic lymphoma; CGDTCL, cutaneous gamma delta T cell lymphoma

^*Other histologic subtypes included one case of ALK-negative anaplastic large cell lymphoma and NK/T cell lymphoma